Bookkeeping. I added Pfizer as the first of 10 picks in my Special Report A New World for Dividends. You can find this write up on that long Special Reports post. But I want to make no one misses that pick and update.
Let’s say you’re a dividend income investor. You need cash income in retirement. Or you want your portfolio to generate cash now so you can invest in new opportunities. Or you just want the extra safety and lower risk that owning a stock with a substantial dividend can bring. Whatever your reasons–and I can think of a lot more–this is a particularly challenging financial market for dividend income investors.But I do think there are strategies dividend income investors can successfully pursue even in this challenging market. In the rest of this Special Report I’m going to explain the three ways I think you should be thinking about dividend income investing in this market. And then I’m going to give you 10 dividend stocks that I think are especially well-suited to producing income (and price appreciation, which is always nice even if you’re an income investor) in this market environment. First pick just posted–Pfizer
I’m extremely reluctant to add any stocks to any portfolios right now. There’s just too much near-term uncertainty and we remain locked in the grip of a pushing Bear Market. But I do want to upgrade my portfolios when possible to increase their future upside. So tomorrow September 28, I’ll be adding shares of drug maker Eli Lilly (LLY) to my Jubak Picks Portfolio; To make this an upgrade rather than an addition to this portfolio, I will also be selling shares of biotech Incyte (INCY) out of that portfolio. In this paired trade I think I’m adding a comparatively stronger drug pipeline to my holdings.
The federal government has agreed to purchase 105 million doses of Pfizer-BioNTech’s rebooted vaccine for $3.2 billion, the Washington Post reported on Friday. At $30.50 a dose, that’s a premium over the initial contracts the government made for the original vaccine in 2020, when the vaccines were $19.50 per dose. the government is expected to sign a new contract with Moderna (MRNA) shortly. Pfizer (PFE) is a member of my Dividend Portfolio. The shares are up 35.14% since I added them to the portfolio on August 28, 2020. The stock is down 11.89% year-to-date for 2022 as of the close on Friday, July 22. However, they are up 4.40% in the last month. Pfizer pays a 3.12% dividend.
The advice is sound, very sound. Move part (at least of your portfolio to cash and sit out the worst of this bear market on the sidelines. And since you have that cash in hand, you’ll be ready to snap up bargains when the market has put in a bottom (or near the bottom, or on the way up from the bottom…or something.) But right now that’s easier said than done.
Pfizer (PFE) will buy privately held respiratory syncytial virus drug maker ReViral for up to $525 million. Wall Street liked the deal–the stock was up 4.33% today, April 7–because it fits with Pfizer’s RNA virus program, which produced a successful vaccine for Covid-19.
Yesterday the Standard & Poor’s 500 fell 1.14% and market leading stocks such as Applied Materials (AMAT) dropped 0.78%. Big drug stocks made up the only sector in the green as Pfizer (PFE) rose 2.59%,and AbbVie (ABBV) gained 1.23%. The fears yesterday were that the Omicron Variant of the Covid-19 virus would slow the economy and that Senator Joe Manchin had just killed prospects for any stimulus from the Biden Administration’s Build Back Better bill. Today the S&P 500 closed up 1.78%. A market leader like Applied Materials rose 4.42%. A big drug stock such as Pfizer was down 3.39%.
It’s actually surprising that markets aren’t down more so far today. As of noon New York time, the Standard & Poor’s 500 is lower by 1.62% and the Dow Jones Industrial Average is down 1.75%. The NASDAQ Composite has lost 1.65% and the NASDAQ 100 has dropped 1.34%. The small cap Russell 2000 has tumbled 2.43% and the iShares Emerging Markets ETF (EEM) has fallen 1.85%. No place to hide. (Well, maybe big drug company stocks.)
Executives at Pfizer (PFE), which, remember, makes a Corona-19 vaccine–said yesterday, December 8, that the new Omicron Variant could increase the likelihood that people will need a fourth coronavirus vaccine dose earlier than expected.
I’m starting up my videos on JubakAM.com again–this time using YouTube as a platform. My seventy-fifth YouTube video “4 Picks for the Omicron Wave” went up today.
I’m starting up my videos on JubakAM.com again–this time using YouTube as a platform. My sixty-ninth YouTube video “Trend of the Week Big Pharma for Safety” went up today.
I’m starting up my videos on JubakAM.com again–this time using YouTube as a platform. My sixty-seventh YouTube video “7 Picks for a Confused Market” went up today.
